MK4280A-700
09 Dec 2020
MK4280A-700
–
A phase 3 study of MK-4280 plus MK-3475 (pembrolizumab) vs. regorafeneb in 3L+ mCRC
–
Cancer Type | Bowel and colon |
---|---|
Trial Type | Treatment |
Phase | Phase III |
Age Range | 18 years and older |
Sex | Both |
Tumour Stream | - |
Cancer Stage | All stages |
Anticipated Start Date | - |
Anticipated End Date | - |
Hospital | The Queen Elizabeth Hospital |
---|---|
Clinical Trial Coordinator | Pamela Cooper |
pamela.cooper@sa.gov.au | |
Phone | 08 8222 6140 |
Principal Investigator | Professor Tim Price |
Recruitment Status | Not Yet Recruiting |
Keep up to date with the latest news and breakthroughs